Hepatitis C virus (HCV) infects an estimated 50 million people worldwide, according to the World Health Organization, and remains a leading cause of cirrhosis and liver cancer. While antiviral drugs ...

Hepatitis C is the leading cause of chronic liver disease and liver cancer in the world and affects an estimated 51 million people globally. Though the viral infection is easily diagnosable and ...

A case of a 45-year-old construction worker with a history of intravenous drug use, homelessness, and occasional alcohol and tobacco use.

Advanced Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV) in 2025 with Topline Results from North American C-BEYOND Trial Expected ...

In the wake of recent breakthroughs in the management of hepatitis C virus (HCV) infection, with several new promising medications available on the market and more being studied in clinical trials, it ...

Please provide your email address to receive an email when new articles are posted on . Chronic HCV infection was associated with a 1.8-fold increased risk for pancreatic ductal adenocarcinoma.

In previous articles of this series, we’ve discussed several aspects of the hepatitis C virus including the nature of the infection and its distribution both globally and in the United States. Most ...

The 2022 World Health Organization (WHO) report estimated 58 million people live with chronic hepatitis C, while approximately 40% of people are unaware of their infection. The hepatitis C virus (HCV) ...

Among rural people with chronic HCV infection and a history of injection drug use, a mobile telemedicine-based intervention vs enhanced usual care improves treatment initiation and cure rates.

Given that HCV is a bloodborne virus, any circumstance that promotes continued drug injection—including failure to prevent or diagnose and adequately treat substance use disorders—can result in ...

Cash and Investments -- $301.8 million as of December 31, 2025, sufficient to fully fund current Phase III HCV and new HEV programs through 2027. Phase III HCV Trials -- C BEYOND enrollment completed ...